Compare SUVEN LIFE with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES ORCHID PHARMA LTD SUVEN LIFESCIENCES/
ORCHID PHARMA LTD
 
P/E (TTM) x 19.4 -0.5 - View Chart
P/BV x 3.9 0.1 3,344.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFESCIENCES   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
ORCHID PHARMA LTD
Sep-13
SUVEN LIFESCIENCES/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs338194 174.1%   
Low Rs16935 484.0%   
Sales per share (Unadj.) Rs52.1276.5 18.9%  
Earnings per share (Unadj.) Rs6.8-79.2 -8.6%  
Cash flow per share (Unadj.) Rs8.6-43.5 -19.7%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.353.9 121.0%  
Shares outstanding (eoy) m127.2870.45 180.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.90.4 1,174.4%   
Avg P/E ratio x37.1-1.4 -2,567.9%  
P/CF ratio (eoy) x29.6-2.6 -1,122.7%  
Price / Book Value ratio x3.92.1 182.9%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,2728,067 400.1%   
No. of employees `0001.12.8 38.6%   
Total wages/salary Rs m6612,527 26.2%   
Avg. sales/employee Rs Th6,132.26,956.1 88.2%   
Avg. wages/employee Rs Th611.1902.5 67.7%   
Avg. net profit/employee Rs Th803.5-1,993.0 -40.3%   
INCOME DATA
Net Sales Rs m6,63519,477 34.1%  
Other income Rs m242407 59.5%   
Total revenues Rs m6,87719,884 34.6%   
Gross profit Rs m1,6041,103 145.5%  
Depreciation Rs m2212,519 8.8%   
Interest Rs m385,227 0.7%   
Profit before tax Rs m1,587-6,236 -25.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m718-125 -573.5%   
Profit after tax Rs m869-5,580 -15.6%  
Gross profit margin %24.25.7 427.1%  
Effective tax rate %45.22.0 2,252.9%   
Net profit margin %13.1-28.7 -45.7%  
BALANCE SHEET DATA
Current assets Rs m6,23211,014 56.6%   
Current liabilities Rs m1,49032,060 4.6%   
Net working cap to sales %71.5-108.1 -66.1%  
Current ratio x4.20.3 1,217.4%  
Inventory Days Days8695 91.1%  
Debtors Days Days8334 246.2%  
Net fixed assets Rs m4,04329,440 13.7%   
Share capital Rs m127705 18.1%   
"Free" reserves Rs m8,1832,043 400.6%   
Net worth Rs m8,3103,800 218.7%   
Long term debt Rs m189,018 0.2%   
Total assets Rs m10,38946,510 22.3%  
Interest coverage x43.1-0.2 -22,320.9%   
Debt to equity ratio x02.4 0.1%  
Sales to assets ratio x0.60.4 152.5%   
Return on assets %8.7-0.8 -1,148.8%  
Return on equity %10.5-146.9 -7.1%  
Return on capital %19.5-3.7 -522.5%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m5,6227,513 74.8%   
Fx outflow Rs m1,7995,649 31.9%   
Net fx Rs m3,8221,865 205.0%   
CASH FLOW
From Operations Rs m3561,682 21.1%  
From Investments Rs m-279-9,860 2.8%  
From Financial Activity Rs m-2256,644 -3.4%  
Net Cashflow Rs m-148-1,535 9.7%  

Share Holding

Indian Promoters % 63.4 32.3 196.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.6 -  
FIIs % 0.0 3.3 -  
ADR/GDR % 0.0 4.6 -  
Free float % 36.5 55.3 66.0%  
Shareholders   37,287 84,811 44.0%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 20, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS